Navigation Links
23andMe sarcoma research community reaches 500 and announces Sarcoma Scientific Advisory Committee
Date:1/25/2011

MOUNTAIN VIEW, CA January 25, 2011 23andMe's sarcoma research efforts are well underway with collection of both phenotypic and genetic data from 500 individuals diagnosed with sarcoma already completed. The company is half way towards its goal of building a sarcoma research community of more than 1,000 individuals. 23andMe has also completed its Independent Sarcoma Scientific Advisory Committee with the appointment of leading researchers and clinicians, including Robert Maki, MD, PhD, George Demetri, MD, Judy Garber, MD, MPH, and Mark Robson, MD.

"Members of our independent, external Sarcoma Advisory Committee bring unsurpassed expertise of sarcoma and cancer genetics to our research efforts," said Anne Wojcicki, 23andMe co-founder and CEO. "We are confident that together, we will meaningfully advance our current understanding of sarcomas."

Sarcomas are a rare group of cancers that arise in connective tissues (such as muscle, fat, cartilage, tendons and blood vessels) or in bone. It is estimated that there are approximately 13,000 cases of Sarcoma seen annually in the United States. This is an extremely small number compared to the total of more than 1.4 million people who are diagnosed with cancer each year in the United States. The small number of cases seen, the diversity in the biology of each type of sarcoma, and other variables make identifying and understanding causes of Sarcomas particularly difficult.

23andMe's Sarcoma research efforts first began in April 2010, inviting current and former sarcoma patients to participate by being genotyped and completing surveys about their disease and treatment response through the 23andMe web-based research platform, under approval from an Institutional Review Board (IRB). Participants receive access to the full 23andMe experience, including information about their genetic ancestry as well as access to all 184 health and trait reports at no charge.

As 23andMe coll
'/>"/>

Contact: Jane E. Rubinstein
jrubinstein@rubenstein.com
212-843-8287
23andMe Inc.
Source:Eurekalert  

Page: 1 2

Related biology news :

1. 23andMe presents top 10 most interesting genetic findings of 2010
2. 23andMe receives NIH funding to evaluate web-based research on the genetics of drug response
3. Genetically reprogrammed HSV given systemically shrinks distant sarcomas
4. Potential new drug target to combat Kaposis sarcoma
5. UCSF researchers identify new drug target for Kaposis sarcoma
6. Purdue team creates engineered organ model for breast cancer research
7. Blue crab research may help Chesapeake Bay watermen improve soft shell harvest
8. Research into synthetic antibodies offers hope for new diagnostics
9. ASM Biodefense and Emerging Diseases Research Meeting
10. Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers
11. Climate change threatens many tree species, say Hebrew U. researchers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
23andMe sarcoma research community reaches 500 and announces Sarcoma Scientific Advisory Committee
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... a new study, Dartmouth researchers describe the structure of a ... Vibrio cholerae , the bacteria that causes cholera. Buried within ... that appears to inhibit ToxT, which prevents the bacteria from ... threatening, and, according to the World Health Organization, cholera remains ...
... In fact, toe running is far more efficient than landing ... distance endurance running, humans are some of the best-adapted animals ... why have we stuck with our inefficient heel first footfall ... marathon running? This paradox puzzled Nadja Schilling and Christoph Anders ...
... Scientists have pinpointed specific mutations that allow a common ... in the March issue of the Journal of General ... viruses and hosts could provide insight to how some viruses ... a better idea of how animal diseases are generated. ...
Cached Biology News:Dartmouth researchers describe how the cholera bacteria becomes infectious 2Human use heel first gait because it is efficient for walking 2The genetic secrets to jumping the species barrier 2
(Date:7/27/2015)... ... July 27, 2015 , ... This is ... report provides a basic overview of the industry including definitions, classifications, applications and ... including development trends, competitive landscape analysis, and key regions development status. Development policies ...
(Date:7/27/2015)... --  Inocucor Technologies Inc ., the agriculture biotech ... has received a notice of allowance from the ... application to protect Inocucor consortia and unique microbial ... on farms and in greenhouses. This ... consortium and its fermentation byproducts, which are the ...
(Date:7/27/2015)... , July 27, 2015 According to ... Type (Home-brew Media, Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, ... Europe , Asia-Pacific , ... The global biopreservation media market was valued at $247.7 million ... million by 2019, at a CAGR of 18.2% between 2014 ...
(Date:7/27/2015)... WESTBROOK, Maine , July 27, 2015 ... that more than 8,000 clinics have submitted over 100,000 ... SDMA, testing in just the first 10 days since ... Chronic kidney disease (CKD) is a leading cause of ... from the submitted specimens are consistent with generally accepted ...
Breaking Biology Technology:2015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5
... RIVER, N.Y., June 20, 2011 ... provider of software and services for health and ... 4.2 electronic health record (EHR) software for behavioral ... ARRA Ambulatory Certification. (Logo: http://photos.prnewswire.com/prnh/20110620/NY22778LOGO) ...
... VICTORIA, Australia, June 20, 2011 Genetic Technologies Limited ... North American division, Phenogen Sciences Inc., has launched the ... risk.   Phenogen Sciences will target its ... US metro-markets.  The company has deployed its sales force ...
... ,Graphene, a one-atom-thick layer of graphitic carbon, has the ... But its unique properties, and the shrinking scale of ... produce on a large scale. In ... had overcome some of these difficulties and were able ...
Cached Biology Technology:CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 2CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 3CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 4Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 2Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 4UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits 2
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
... antibody raised against a partial ... Immunogen: SLC22A3 (NP_068812, 90 ... recombinant protein with GST tag. ... NM_021977 ...
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
Biology Products: